This episode’s Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow’ Sustainability Campaign, and how you can get involved: CLICK HERE
---
Episode Overview:
Is it possible to revolutionize kidney disease treatment and redefine conventional care? Our next guest, John Erbey, is doing just that as the founder and CEO of Roivios.
With over 25 years of pioneering experience in the medical field, John brings a unique blend of analytical rigor, physiological insight, and deep understanding of customer needs, which has driven ground-breaking advancements across the medical device and pharmaceutical sectors.
Inspired by personal experiences with kidney disease in his family, John is on a mission to transform patient lives.
Join us as we explore how Roivios is reshaping kidney health management, potentially saving billions in healthcare costs, and paving the way for a future where kidney function can be sustained and enhanced. Let's go!
Episode Highlights:
- Embracing discomfort for true innovation in healthcare
- Addressing kidney disease's $250 billion annual cost in the US
- Targeting renal impairment during cardiac surgery
- Developing JuxtaFlow technology with future wearable applications
- Envisioning implantable devices to prevent kidney disease progression
About our Guest:
John Erbey, a visionary with over 25 years of experience in the medical field, is the founder and CEO of Roivios. His dynamic leadership and pioneering approaches have led to substantial advancements in therapeutic development and medical devices.
At Roivios, John has revolutionized the treatment of kidney disease by introducing an innovative approach that redefines conventional wisdom about kidney filtration. This led to the creation of the groundbreaking JuxtaFlow® Renal Assist Device (RAD), marking a significant evolution in kidney health management.
John's leadership extends across the medical device and pharmaceutical sectors, where he has led the launch of CardioMEMS and defined the EU pricing strategy for Ezetrol (Zetia). As a strategist, his mission is to enhance patient lives by providing superior tools to healthcare providers. His unique blend of analytical rigor, physiological insight, and deep understanding of customer needs has enabled him to leverage scientific innovations, creating value for brands like CardioMEMS™, Zetia™, Vytorin™, and Avandia™.
Since founding Roivios in 2015, John's personal journey has been a driving force behind his commitment to transformative healthcare solutions. Having witnessed the profound effects of kidney failure within his own family and through poignant stories shared by potential investors, John's resolve to make a positive impact on patients facing similar challenges has only strengthened over time.
John holds a Ph.D. in epidemiology from the University of Pittsburgh’s Graduate School of Public Health, where his groundbreaking research in this field has earned him induction into Delta Omega, the prestigious National Honor Society for Public Health.
Links Supporting This Episode:
